Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Calvin Mein
Jaeb Center for Health Research, Inc., Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Novartis
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
SFI is with a company that manufactures a product that is being used in a clinical trial conducted under this grant
DRCR Network
Project Narrative (3 Sentences) Visual impairment and blindness from retinal diseases remain a significant public health problem that continues to grow in epidemic proportions in the United States and globally despite advances in treatment. The DRCR.net is collaborative research network dedicated to multicenter clinical research of diabetic retinopathy, age-related macular degeneration, hereditary retinal degenerations and other retinal diseases of public health importance through the identification, creation, implementation, analysis and reporting of high quality clinical studies that lead to a better understanding of retinal diseases, advance their treatment, and positively improve the lives of individuals with retinal pathology. DRCR.net studies addressing novel treatments for diabetic macular edema and proliferative diabetic retinopathy have already had a major direct impact on clinical care guidelines and practices worldwide for diabetic eye disease, making the Network uniquely poised for further impactful contributions in the fight against vision loss from retinal diseases.
Filed on May 22, 2019.
Tell us what you know about Calvin Mein's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Calvin Mein”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Calvin Mein | Pennsylvania State Univ Hershey Med Ctr | Conflict of Interest | Regeneron Pharmaceuticals | $150,000 - $199,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.